During the Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting Thursday, Martin said there were two anaphylaxis reactions among the volunteers in Moderna’s late-stage trial, but the company does not think its vaccine-related.
"We have actively scrutinized our safety data to identify and analyze possible cases of anaphylaxis. We found no cases suggestive of anaphylaxis to mRNA 1273," Martin said.
One severe allergic reaction was in the placebo group and one was in the group that got the vaccine.
The allergic reaction in the placebo group happened 10 days after the volunteer got their first dose of the placebo. Doctors believed the allergic reaction was a reaction to a dye used in the placebo.
The person in the vaccine group had a severe allergic reaction 63 days after they got the second dose of the vaccine. This person has a history of asthma and is allergic to shellfish.